Golden State Medical Supply Inc.
Complete recall history across all FDA and CPSC categories — 50 total recalls
Golden State Medical Supply Inc. appears in recall records across 1 category. This page consolidates all FDA food, drug, and medical device enforcement actions, plus CPSC consumer product recalls associated with this company. Recall data is sourced from openFDA and CPSC public databases.
Drug Recalls (50)
FDA drug safety enforcement actions by Golden State Medical Supply Inc.
| Date | Product | Reason | Class |
|---|---|---|---|
| Apr 27, 2026 | Primidone Tablets, USP, 250 mg, 100-count bottle, RX only, Manufactured by: L... | Cross contamination with other products: API contaminated with trace amounts ... | Class III |
| Apr 27, 2026 | Primidone Tablets, USP, 50 mg, 50-count bottle, RX only, Manufactured by: Lan... | Cross contamination with other products: API contaminated with trace amounts ... | Class III |
| Nov 26, 2025 | Baclofen Tablets USP, 10 mg, 1000-count bottles, Rx only, Marketed by: GSMS, ... | Presence of Foreign Tablets/Capsules | Class II |
| Oct 20, 2025 | NIACIN Extended-Release Tablets, USP, 1,000 mg, 90 tablets per bottle, Rx onl... | Failed Dissolution Specifications | Class II |
| Mar 5, 2025 | PRASUGREL TABLETS, 5 mg, 30 tablet bottles, Rx only, packaged by GSMS, Incorp... | Failed Dissolution Specifications | Class II |
| May 13, 2024 | Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, a) 30 capsules bottl... | CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity (NDS... | Class II |
| Feb 14, 2024 | Fluticasone Propionate Nasal Spray USP, 50 mcg per spray, 120 metered sprays,... | CGMP Deviations:Suspected potential presence of Burkholderia cepacia complex | Class II |
| Jan 12, 2024 | Budesonide Extended-Release Tablets, 9 mg, 30-count bottles, Rx only, Markete... | Failed Dissolution Specifications | Class II |
| Nov 10, 2023 | PAROXETINE tablets, USP, 20 mg, Packaged as a) 90-count bottle NDC 60429-735-... | Failed Impurities/Degradation Specifications-Manufacturer Apotex Inc. recalli... | Class II |
| Nov 10, 2023 | PAROXETINE tablets, USP, 40 mg, Packaged as a) 30-count bottle, NDC 60429-73... | Failed Impurities/Degradation Specifications-Manufacturer Apotex Inc. recalli... | Class II |
| Nov 10, 2023 | PAROXETINE tablets, USP, 10 mg, Packaged as a) 30-count bottle, NDC 60429-73... | Failed Impurities/Degradation Specifications-Manufacturer Apotex Inc. recalli... | Class II |
| May 25, 2023 | Travoprost Ophthalmic Solution, USP (Ionic Buffered Solution), 0.004%, Rx onl... | Lack of Assurance of Sterility: Tamper Evidence Seal is missing on secondary ... | Class II |
| Oct 6, 2022 | Rifampin Capsules, USP, 300 mg, packaged in a) 30-count bottle (NDC 51407-323... | Failed impurities/degradation specifications: Finished product exceeds the 5 ... | Class II |
| Oct 6, 2022 | Rifampin Capsules, USP, 150 mg, 30-count bottle, Rx only, Manufactured by Pat... | Failed impurities/degradation specifications: Finished product exceeds the 5 ... | Class II |
| Sep 29, 2022 | Atenolol Tablets, USP, 25 mg, 1000-count bottle, Rx only, Manufactured by: AL... | Label Mix - up; a bottle labeled as Atenolol 25mg Tablets contained Clopidogr... | Class I |
| Mar 16, 2022 | Enalapril Maleate Tablets, USP; 20 mg; 90 tablets, NDC 60429-186-90; manufact... | CGMP Deviations | Class II |
| Mar 16, 2022 | Enalapril Maleate Tablets, USP; 5 mg; 90 tablets, NDC 60429-184-90; manufactu... | CGMP Deviations | Class II |
| Mar 16, 2022 | Enalapril Maleate Tablets, USP; 10 mg; 90 tablets, NDC 60429-185-90; manufact... | CGMP Deviations | Class II |
| Mar 16, 2022 | Enalapril Maleate Tablets, USP; 2.5 mg; 90 tablets, NDC 60429-183-90; manufac... | CGMP Deviations | Class II |
| Mar 2, 2022 | Alprazolam Tablets, USP 1mg, 180-count bottles, Rx only, Manufactured by ULTR... | CGMP Deviation: Potential cross-contamination with other drug substance durin... | Class II |
| Oct 14, 2021 | Ezetimibe and Simvastatin Tablets, 10 mg/80mg, 500 tablet bottles, Rx only, M... | Failed Excipient Specification; product manufactured using an excipient found... | Class II |
| Oct 14, 2021 | Ezetimibe and Simvastatin Tablets, 10 mg/40mg, a) 90 Tablets, b) 500 tablets,... | Failed Excipient Specifications and Presence of Foreign Tablets/Capsules; pro... | Class II |
| Mar 19, 2021 | Omeprazole Delayed Release Capsules, USP, 20 mg, 1000-count bottles, Rx only,... | Failed Impurities/Degradation Specifications: Out of Specification results ob... | Class II |
| Nov 17, 2020 | ARIPIPRAZOLE TABLETS, 15 mg, 30-count. bottles, Rx Only, GSMS Incorporated, M... | FAILED DISSOLUTION SPECIFICATIONS: Possibility of out-of-specification (OOS) ... | Class II |
| Jul 24, 2020 | Clobetasol Propionate Cream, USP, 0.05%, packaged in a)15g Tubes (NDC 60429-9... | Failed Content Uniformity: bulk lot used to make these two lots was found to ... | Class III |
| Apr 3, 2020 | Losartan Potassium Tablets, USP, 25 mg, Rx only, a) 30 ct. (NDC 60429-316-30)... | CGMP Deviations: Impurity for N-nitroso-N-methyl-4-aminobutryric Acid (NBMA) ... | Class II |
| Feb 12, 2020 | TRAMADOL HYDROCHLORIDE Tablets, USP, 50 mg, Rx Only a)100-count bottles (NDC ... | Labeling: Incorrect package insert - Patient leaflets for the specified lots ... | Class III |
| Nov 6, 2019 | GSMS: Ranitidine Capsules 300 mg, Rx only, 100 count bottles (NDC 51407-098-0... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II |
| Nov 6, 2019 | GSMS: Ranitidine Capsules 150 mg, Rx only, 500 count bottles (NDC 51407-097-0... | CGMP Deviations: Presence of NDMA impurity detected in product. | Class II |
| Jun 14, 2019 | Losartan Potassium, 50 mg tablets, 90 count bottle, NDC 60429-317-90 | CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) d... | Class II |
| Jun 14, 2019 | Losartan Potassium, 100 mg tablets, 90 count bottle, NDC 60429-318-90 | CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) d... | Class II |
| Jun 14, 2019 | Losartan Potassium, 50 mg tablets, 30 count bottle, NDC 60429-317-30 | CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) d... | Class II |
| Jun 14, 2019 | Losartan Potassium, 50 mg tablets, 1000 count bottle, NDC 60429-317-10 | CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) d... | Class II |
| May 1, 2019 | Losartan Potassium Tablets USP 25 mg 90 count bottle NDC 60429-316-90 Rx only... | CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobu... | Class II |
| May 1, 2019 | Losartan Potassium Tablets USP 100 mg 90 count bottle NDC 60429-318-90 Rx onl... | CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobu... | Class II |
| May 1, 2019 | Losartan Potassium Tablets USP 100 mg 1000 count bottle NDC 60429-318-10 Rx o... | CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobu... | Class II |
| May 1, 2019 | Losartan Potassium Tablets USP 25 mg 1000 count bottle NDC 60429-316-10 Rx on... | CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobu... | Class II |
| May 1, 2019 | Losartan Potassium Tablets USP 25 mg 30 count bottle NDC 60429-316-30 Rx only... | CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobu... | Class II |
| Nov 2, 2018 | IRBESARTAN Tablets, USP 75 mg 90-count bottle, Rx Only, Manufactured by: SciG... | CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-... | Class II |
| Nov 2, 2018 | IRBESARTAN Tablets, USP 150 mg (a) 30-count bottle (NDC 60429-641-30), (b) 90... | CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-... | Class II |
| Nov 2, 2018 | IRBESARTAN Tablets, USP 300 mg (a) 30-count bottle (NDC 60429-642-30), (b) 90... | CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-... | Class II |
| Aug 3, 2016 | Venlafaxine Hydrochloride Extended-Release Capsules, 75 mg, 90 capsules per ... | Failed Dissolution Specifications: Out-of-specification results in retained s... | Class II |
| Aug 3, 2016 | Venlafaxine Hydrochloride Extended-Release Capsules, 150 mg, a) 30 capsules p... | Failed Dissolution Specifications: Out-of-specification results in retained s... | Class II |
| Jun 28, 2016 | DULOXETINE Delayed-Release Capsules, USP, 60 mg, 1000 count bottles, Rx only,... | Labeling; Incorrect or Missing Lot and/or Exp Date; incorrect expiration date... | Class III |
| Jan 27, 2016 | Atorvastatin Calcium 80 mg, 10 tablets per blister,100-count package, Rx Only... | Failed Impurities/Degradation Specifications | Class III |
| Jan 27, 2016 | Atorvastatin Calcium 20 mg, 10 tablets per blister,100-count package, Rx Only... | Failed Impurities/Degradation Specifications | Class III |
| Jan 27, 2016 | Atorvastatin Calcium 10 mg, 10 tablets per blister,100-count package, Rx Only... | Failed Impurities/Degradation Specifications | Class III |
| Jan 27, 2016 | Atorvastatin Calcium 40 mg, 10 tablets per blister,100-count package, Rx Only... | Failed Impurities/Degradation Specifications | Class III |
| Nov 25, 2015 | MECLIZINE HYDROCHLORIDE TABLETS, 12.5 mg, Packaged in 1000 ct Bottles, Rx Onl... | Failed Impurities/Degradation Specifications: Out of specification for impuri... | Class III |
| Nov 25, 2015 | MECLIZINE HYDROCHLORIDE TABLETS, 25 mg, Packaged in a) 100 ct Bottles (NDC: 6... | Failed Impurities/Degradation Specifications: Out of specification for impuri... | Class III |
Frequently Asked Questions
A high number of recalls does not necessarily indicate that a company is unsafe. Large manufacturers that produce thousands of products across multiple categories will statistically appear in recall databases more frequently. What matters more is the severity of each recall (Class I being the most serious), the speed of response, and whether the company proactively identified and addressed the issue. Companies with robust safety programs often catch problems earlier.
Food, drug, and medical device recall data comes from the FDA's openFDA enforcement database, which contains all FDA enforcement reports. Consumer product recall data comes from the U.S. Consumer Product Safety Commission (CPSC). Both sources are public government databases that are updated regularly. RecallCheck aggregates these sources to provide a unified view of a company's recall history.
The FDA classifies recalls into three categories. Class I is the most serious — there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. Class II means the product may cause temporary or medically reversible health problems, or the probability of serious consequences is remote. Class III is the least serious — the product is unlikely to cause adverse health consequences. CPSC product recalls do not use this classification system.
Yes. You can search for any company using the firm/manufacturer pages for each category: Food Firms, Drug Firms, Device Firms, or Product Manufacturers. You can also use the search functionality on any browse page to find recalls by company name.
Explore More Recalls
Search recalls by category, state, reason, or firm across all our databases.